Cargando…

Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer()

Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations and epidermal growth factor receptor (EGFR) family signaling are drivers of tumorigenesis in pancreatic ductal adenocarcinoma (PDAC). Previous studies have demonstrated that combinatorial treatment of PDAC xenografts with the mitogen-activa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindberg, James M., Newhook, Timothy E., Adair, Sara J., Walters, Dustin M., Kim, Alison J., Stelow, Edward B., Parsons, J. Thomas, Bauer, Todd W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198828/ https://www.ncbi.nlm.nih.gov/pubmed/25117978 http://dx.doi.org/10.1016/j.neo.2014.06.004

Ejemplares similares

Clinical, Molecular and Genetic Validation of a Murine Orthotopic Xenograft Model of Pancreatic Adenocarcinoma Using Fresh Human Specimens
por: Walters, Dustin M., et al.
Publicado: (2013)

MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX)
por: Kawaguchi, Kei, et al.
Publicado: (2017)

Trametinib: a MEK inhibitor for management of metastatic melanoma
por: Lugowska, Iwona, et al.
Publicado: (2015)

MEK inhibition with trametinib is a successful therapy in ganglioglioma
por: Daniel, Eliza Baird, et al.
Publicado: (2020)

MODL-27. MEK INHIBITION WITH TRAMETINIB SLOWS PROGRESSION OF MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR IN ORTHOTOPIC XENOGRAFT MURINE MODEL
por: Mushrif, Sujata, et al.
Publicado: (2020)

Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction
por: Unsworth, Amanda J., et al.
Publicado: (2018)

Structural basis for the action of the drug trametinib at KSR-bound MEK
por: Khan, Zaigham M., et al.
Publicado: (2020)

The MEK Inhibitor Trametinib Suppresses Major Histocompatibility Antigen-mismatched Rejection Following Pancreatic Islet Transplantation
por: Tada, Seiichiro, et al.
Publicado: (2020)

A Thirteen-Gene Expression Signature Predicts Survival of Patients with Pancreatic Cancer and Identifies New Genes of Interest
por: Newhook, Timothy E., et al.
Publicado: (2014)

Isotretinoin for the treatment of severe acneiform eruptions associated with the MEK inhibitor trametinib
por: Caruana, Marco, et al.
Publicado: (2020)

Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis
por: Aaroe, Ashley, et al.
Publicado: (2023)

Computational Study on the Effect of Inactivating/Activating Mutations on the Inhibition of MEK1 by Trametinib
por: Zhu, Jingxuan, et al.
Publicado: (2020)

The MEK Inhibitor Trametinib Improves Outcomes following Subarachnoid Haemorrhage in Female Rats
por: Bömers, Jesper Peter, et al.
Publicado: (2022)

Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab
por: Taniguchi, Hiroya, et al.
Publicado: (2018)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
por: Zhang, Mengqi, et al.
Publicado: (2022)

Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma
por: Laino, Antonia, et al.
Publicado: (2018)

Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs
por: Wei, Bih-Rong, et al.
Publicado: (2022)

The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes
por: Lulli, Daniela, et al.
Publicado: (2017)

ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells
por: Zhou, Sheng, et al.
Publicado: (2018)

PB2282: MEK-KINASE INHIBITOR (TRAMETINIB) AS A TREATMENT OPTION FOR HAIRY CELL LEUKEMIA
por: Smirnova, Svetlana, et al.
Publicado: (2023)

Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model
por: Kawaguchi, Kei, et al.
Publicado: (2016)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2018)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2017)

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
por: Lim, Bora, et al.
Publicado: (2021)

Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma
por: Schulz, Alexander, et al.
Publicado: (2022)

Successful treatment of refractory chylothorax with MEK inhibitor trametinib in a child with Noonan syndrome: case report
por: Hribernik, Ines, et al.
Publicado: (2023)

Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors
por: Arkenau, Hendrik‐Tobias, et al.
Publicado: (2022)

Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft
por: Zhang, Anli, et al.
Publicado: (2010)

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
por: King, Alastair J., et al.
Publicado: (2013)

Lasting response by vertical inhibition with cetuximab and trametinib in KRAS‐mutated colorectal cancer patient‐derived xenografts
por: Reissig, Timm M., et al.
Publicado: (2023)

CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response
por: Szlachta, Karol, et al.
Publicado: (2018)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Immunogenicity of panitumumab in combination chemotherapy clinical trials
por: Weeraratne, Dohan, et al.
Publicado: (2011)

Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(Δ716) mice involves stromal COX-2
por: Fujishita, Teruaki, et al.
Publicado: (2015)

Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib
por: Florent, Romane, et al.
Publicado: (2020)

LGG-30. TRAMETINIB-ASSOCIATED HYPONATREMIA IN A CHILD WITH LOW GRADE GLIOMA IS NOT SEEN FOLLOWING TREATMENT WITH ALTERNATIVE MEK INHIBITOR
por: Lazow, Margot A, et al.
Publicado: (2020)

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, (111)In or β-particle emitting, (177)Lu
por: Aghevlian, Sadaf, et al.
Publicado: (2020)

Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months
por: Marconcini, Riccardo, et al.
Publicado: (2017)

Trastuzumab‐based near‐infrared photoimmunotherapy in xenograft mouse of breast cancer
por: Yamashita, Susumu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c2bhsgeo2gqgpuojd1qm8jp1s0